Emerging data suggest Retatrutide , a dual stimulator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could provide a significant step forward for obesity treatment. Preliminary clinical investigations have indicated considerable losses in abdominal fat , conceivably exceeding current weight-loss medications . H